Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0848771 (
neurological disability
)
928
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ischemic stroke is a devastating condition with a high burden of
neurological disability
and death. The aim of this study was to explore the potential long noncoding RNA (lncRNA) biomarkers underlying the mechanism of stroke. The Subpathway-LNCE method, which was specifically designed to identify lncRNAs competitively regulated functions in diseases, was applied in ischemic stroke dataset to identify ischemic-stroke-associated dysfunctional subpathway that regulated by lncRNAs. At first, based on the shared microRNA (miRNA) between miRNA-messenger RNA (mRNA) and lncRNA-miRNA interactions, lncRNA-mRNA interactions were constructed. Then, the transcription profiling of 18 631 genes was downloaded from Array Express database and was preprocessed, including normalization and gene expression difference (
DEG
) analysis, to identify candidate differential pathways using Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. Next, the pathway-lncRNA-mRNA networks were constructed by linking lncRNAs to candidate differential pathways. At last, there were 11 lncRNAs were identified in the top three subpathways as hub-lncRNAs totally, including LINC00240, LINC00472, LINC00265, LINC00473, MIR497HG, NEXN-AS1, HCG17, MEG8, EPB41L4A-AS1, SNHG7, and BCYRN1, five of which were validated to be very effective stroke biomarker by RT-PCR. In conclusion, we applied Subpathway-LNCE method and experimental verification to identify five lncRNAs, including LINC00265, LINC00473, NEXN-AS1, HCG17, and MEG8, which were considered as important lncRNAs biomarkers in ischemic stroke.
...
PMID:Identification of potential hub-lncRNAs in ischemic stroke based on Subpathway-LNCE method. 3088 37